Healthcare Industry News:  Gamma Knife 

Devices Oncology

 News Release - May 27, 2020

Providence Portland Medical Center Begins Patient Treatments with ViewRay's MRIdian Linac

First MR-Linac in the Pacific Northwest Expands Cancer Patients' Access to MR-Guided Radiation Therapy

CLEVELAND, May 27, 2020 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® MR-Guided Therapy System, a cutting-edge radiation therapy system that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.

The MRIdian system at Providence Portland Medical Center is part of The Elsie Franz Finley Radiation Oncology Center and Providence Cancer Institute. MRIdian utilizes on-table soft tissue imaging to allow oncologists to visualize, adapt and target using diagnostic-quality anatomical detail that is unavailable with conventional image-guided radiation therapy (IGRT) technologies.

Areas of particular interest to the Providence Portland Medical Center are the treatment of non-metastatic pancreatic, liver, and prostate cancer using MRIdian, given the system's real-time MR-guidance and on-table adaptive capabilities.

"This technology allows us to track the movements and monitor changes in shape of the target and surrounding organs so that we can modify the radiation beams to fit the picture of the moment, not yesterday's. It permits stronger, shorter, more effective treatments to be delivered with potentially fewer complications," according to Dr. Steven Seung, Medical Director for Radiation Oncology and Gamma Knife Center of Oregon, and a physician at The Oregon Clinic.

We're pleased to have Providence Portland Medical Center join the growing list of hospitals bringing the benefits of MRIdian to their patients," said Paul Ziegler, Senior Vice President of Sales and Marketing at ViewRay. "As hospitals explore ways to deliver effective cancer treatments while also minimizing patient visits during these challenging times, MRIdian's ability to deliver radiation therapy in fewer treatment sessions becomes even more valuable."

Currently 37 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. More than 9,000 patients have been treated with MRIdian. For a list of treatment centers, please visit:

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2020 and ViewRay's conference calls to discuss its first quarter 2020 and year to date results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and its 2019 Quarterly Reports on Form 10-Q, as updated periodically with the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Source: ViewRay

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.